SGRY: ADJUSTED EBITDA FELL SHY OF MANAGEMENT'S GUIDED PROJECTIONS -- LEVI & KORSINSKY, LLP INVESTIGATES

Surgery Partners reported AN Adjusted EBITDA decline of 4.2% in Q4 following projections for continued expanding margins -- Levi & Korsinsky, LLP investigates potential securities law violations

NEW YORK, March 11, 2026 /PRNewswire/ -- Surgery Partners (NASDAQ: SGRY) investors lost money after the Company's Q4 2025 earnings revealed a significant gap between the adjusted figures management highlighted and the Company's GAAP financial results. Shareholders who suffered a loss are encouraged to submit their information here. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

Last quarter, Surgery Partners emphasized its Adjusted EBITDA of $136.4 million for Q3 2025, representing what CEO Eric Evans called "6.1% growth over the prior year and a margin of 16.6%." The adjusted figures were used to support forward guidance and management's repeated claims of "margin expansion" -- yet SGRY shares dropped sharply when the Company announced that Q4 exhibited an Adjusted EBITDA decline of 4.2%, resulting in a shortfall against management's prior guidance.

Shareholders who purchased SGRY and suffered a loss may click here to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (212) 363-7500

Fax: (212) 363-7171

SOURCE Levi & Korsinsky, LLP